Trial to Evaluate the Safety and Tolerability of Repeated Intravitreal Injection of IBI302 in Neovascular AMD Patients

NCT04370379 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Neovascular Age-related Macular Degeneration

Interventions

DRUG: IBI302 (the first dose level)
DRUG: IBI302 (the second dose level)
DRUG: Aflibercept

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.